Chronic myeloid leukemia · 12 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Asciminib monotherapy Variant #01 | — | R 39 821 | 28d | — | — | — | — | — |
Nilotinib monotherapy Variant #01 | — | R 27 206 | 28d | — | — | — | — | — |
Imatinib monotherapy Variant #17 | — | R 27 014 | 30d | ~20.0 mo | ~53.0 mo | ~21 | ~R 567 284 PFS proxy · indirect | 8 |
Dasatinib monotherapy Variant #01 | — | R 12 899 | 28d | — | — | — | — | — |
BuCyTBI, then allo HSCT Variant #01 | — | R 3 218 | — | — | — | — | — | — |
Cyclophosphamide and TBI, then allo HSCT Variant #01 | — | R 1 176 | — | — | — | — | — | — |
Busulfan monotherapy Variant #01 | — | R 653 | 28d | — | — | — | — | — |
Omacetaxine monotherapy Variant #01 Partial | — | — | 28d | — | — | — | — | — |
Bosutinib monotherapy Variant #01 Partial | — | — | 28d | — | — | — | — | — |
Ponatinib monotherapy Variant #01 Partial | — | — | 28d | — | — | — | — | — |
Interferon alfa-2b and DLI Variant #01 Partial | — | — | — | — | — | — | — | — |
Olverembatinib monotherapy Variant #01 Partial | — | — | 28d | — | — | — | — | — |
12 of 12 regimens shown